{
    "ticker": "RVMD",
    "name": "Reviva Pharmaceuticals Holdings, Inc.",
    "description": "Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders and other serious conditions. Founded in 2011 and based in San Jose, California, Reviva focuses on advancing its proprietary drug candidates through clinical trials to address unmet medical needs. The company\u2019s lead product candidate, RP5063, is being developed for the treatment of schizophrenia, Parkinson's disease, and other CNS-related disorders. Reviva employs a unique approach by leveraging its proprietary technology platform to enhance the efficacy and safety profiles of existing drugs, aiming to provide better treatment options for patients. With a strong commitment to research and development, Reviva is actively engaged in clinical studies to bring its innovative therapies to market. The company\u2019s mission is to improve the quality of life for patients suffering from debilitating conditions by developing safer and more effective treatment alternatives.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Jose, California, USA",
    "founded": "2011",
    "website": "https://www.revivapharma.com",
    "ceo": "Laxminarayan B. Adivi",
    "social_media": {
        "twitter": "https://twitter.com/RevivaPharma",
        "linkedin": "https://www.linkedin.com/company/reviva-pharmaceuticals/"
    },
    "investor_relations": "https://ir.revivapharma.com",
    "key_executives": [
        {
            "name": "Laxminarayan B. Adivi",
            "position": "CEO"
        },
        {
            "name": "Harlan W. Waksal",
            "position": "President and COO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "RP5063"
            ]
        }
    ],
    "seo": {
        "meta_title": "Reviva Pharmaceuticals Holdings, Inc. | Innovative CNS Therapies",
        "meta_description": "Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for CNS disorders. Learn about our mission and lead candidates.",
        "keywords": [
            "Reviva Pharmaceuticals",
            "CNS Disorders",
            "Biopharmaceuticals",
            "Schizophrenia Treatment",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does Reviva Pharmaceuticals do?",
            "answer": "Reviva Pharmaceuticals develops innovative therapies for central nervous system disorders and other serious conditions."
        },
        {
            "question": "Who is the CEO of Reviva Pharmaceuticals?",
            "answer": "Laxminarayan B. Adivi is the CEO of Reviva Pharmaceuticals Holdings, Inc."
        },
        {
            "question": "Where is Reviva headquartered?",
            "answer": "Reviva Pharmaceuticals is headquartered in San Jose, California, USA."
        },
        {
            "question": "What is Reviva's lead product candidate?",
            "answer": "Reviva's lead product candidate is RP5063, developed for the treatment of schizophrenia and other CNS disorders."
        },
        {
            "question": "When was Reviva Pharmaceuticals founded?",
            "answer": "Reviva Pharmaceuticals was founded in 2011."
        }
    ],
    "competitors": [
        "ACAD",
        "SAGE",
        "PTCT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}